AB0414 Relationship between serum oxytocin levels and depression in patients with rheumatoid arthritis. (12th June 2018)

• Record Type: Journal Article
• Authors: Miwa, Y.; Kasama, T.; Sanada, K.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1371
• Page End: 1371
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.3832
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Oxytocin (OXT), also referred to as a happy hormone, has been associated with various psychiatric disorders, including depression. However, the relationship between depression and rheumatoid arthritis (RA) has not yet been clarified. Objectives: The objective of this study was to investigate the relationship between serum oxytocin levels and disease activity, depressive state, activity of daily life (ADL), and quality of life (QOL) in RA. Methods: This study included 119 RA patients. We measured the following variables: baseline characteristics including age, sex, disease duration, smoking history, body mass index, prednisolone dose, and methotrexate (MTX) dose, serum levels of rheumatoid factor, matrix metalloproteinase-3, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level. The disease activity of RA was assessed using the Simplified Disease Activity Index (SDAI); depression was assessed using the Hamilton Depression Rating Scale (HAM-D); ADL were assessed using the Health Assessment Questionnaire; and QOL was assessed using the 36-Item Short Form Health Survey (SF-36). Serum OXT levels were determined by enzyme-linked immunosorbent assay. The subjects were divided into two groups according to the higher or lower of the serum OXT levels, and a retrospective study was performed. Results: The serum OXT levels were correlated with the disease duration (r=0.443, p=0.000). Weak correlations of MTX dose (r=0.208, p=0.030), swollen joint count (SJC) (r=-0.306, p=0.001), ESR (r=-0.245, p=0.010), CRP (r=-0.283, p=0.003) and the mental component summary (MCS) score (r=-0.196, p=0.041) of SF-36. The binominal logistic analyses findings were as follows: younger age (p=0.0209, odd ratio: 0.96, 95% CI: 0.94–0.99) and longer disease duration (p=0.0053, odd ratio: 1.08, 95% CI: 1.02–1.13). Other items did not correlate to the serum OXT levels included with the HAM-D score. Conclusions: The serum oxytocin levels were correlated with longer disease duration and younger age. Acknowledgements: Cooperation on data collection: All Showa University in Rheumatoid Arthritis (ASHURA) group; Nobuyuki Yajima, Takeo Isozaki, Kuninobu Wakabayashi, Ryo Takahashi, Ryo Yanai, Hidekazu Furuya, Takahiro Tokunaga, Sakiko Isojima, Nao Oguro, Yoko Miura, Sho Ishii, Shinya Seki, Mayu Saito, Shinichiro Nishimi, Airi Nishimi, Yuzo Ikari, Mika Hatano, Tomoki Hayashi, Masahiro Hosonuma, Yoichi Toyoshima, Katsunori Inagaki and Kosuke Sakurai Disclosure of Interest: Y. Miwa Grant/research support from: Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, AbbVie CK, Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., Eizai Co., Ltd, Asahi Kasei Pharm Co., Ltd, YL biologics Ltd., Japan Blood Products Organisation, . Ono Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Teijin Pharma Ltd., T. Kasama Grant/research support from: Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, AbbVie CK, Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., Eizai Co., Ltd, Asahi Kasei Pharm Co., Ltd, YL biologics Ltd., Japan Blood Products Organisation, . Ono Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Teijin Pharma Ltd., K. Sanada: None declared